CLAIMS:

1. An effective amount of at least one complex of nocardamine (desferrioxamine E) with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes comprising any carrier/s, matrix or vehicle/s for use in a method for modulating cytokine levels in a cell.

2. The complex of nocardamine (desferrioxamine E) with a metal according to claim 1, wherein said metal is selected from the group consisting of lanthanide/s, actinide/s, post-transition metal/s or transition metal/s.

3. The complex according to claim 2, wherein said metal is selected from the group consisting of zinc, gallium, aluminum, silver, gold, cobalt, molybdenum, vanadium, or any ionic forms thereof.

4. The complex according to claim 3, wherein said metal ion is Zn^{2+}.

5. The complex according to claim 4, wherein said complex is a complex of nocardamine with Zn^{2+}.

6. The complex according to claim 3, wherein said complex is a complex of nocardamine with Ga^{3+}.

7. The complex according to claim 1, wherein said modulation is at least one of reduction or elevation of cytokine levels in said cell.

8. The complex according to claim 7, wherein said cytokine is at least one of, at least one pro-inflammatory cytokine and at least one anti-inflammatory cytokine.

9. The complex according to claim 8, wherein said method reduces the level of at least one pro-inflammatory cytokine in said cell, and wherein said pro-inflammatory cytokine is at least one of: IL-1α, IL-6, TNF- α and IL-17.

10. The complex according to claim 8, wherein said method elevates the level of at least one anti-inflammatory cytokine in said cell and wherein said anti-inflammatory cytokine is at least one of: IL-13, IL-4 and IL-10.

11. The complex according to any one of claims 1 to 6, for modulating cytokine levels in a subject, said method comprising the step of administering to said subject an effective amount of at least one complex of nocardamine with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes comprising any carrier/s, matrix or vehicle/s.

12. The complex according to claim 11, wherein said modulation is reduction of the level of at least one pro-inflammatory cytokine in said subject, said pro-inflammatory cytokine is at least one of IL-1α, IL-6, TNF- α and IL-17.

13. The complex according to claim 11, wherein modulation is elevation of the level of at least one anti-inflammatory cytokine in said subject, said anti-inflammatory cytokine is at least one of IL-13, IL-4 and IL-10.

14. The complex according to claim 11, wherein said subject is suffering from a disorder associated with at least one of elevated level/s of at least one pro-inflammatory cytokine and reduced level/s of at least one anti-inflammatory cytokine.

15. The complex according to claim 14, wherein said disorder is at least one of inflammatory, infectious, autoimmune, proliferative, ischemic, metabolic, neuro-degenerative disorder, spinal cord injury and trauma, and acute or chronic wound or injury.

16. A therapeutically effective amount of at least one complex of nocardamine, with a metal, any combination/s of said complexes, any pharmaceutical composition/s of the complexes comprising any carrier/s, matrix or vehicle/s for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof.

17. The complex of nocardamine (desferrioxamine E) with a metal for use according to claim 16, wherein said metal is selected from the group consisting of lanthanide/s, actinide/s, post-transition metal/s or transition metal/s.

18. The complex according to claim 17, wherein said metal is selected from the group consisting of zinc, gallium, aluminum, silver, gold, cobalt, molybdenum, vanadium, or any ionic forms thereof.

19. The complex according to claim 18, wherein said metal ion is Zn^{2+}.

20. The complex according to claim 19, wherein said complex is a complex of nocardamine with Zn^{2+}.

21. The complex according to claim 18, wherein said complex is a complex of nocardamine with Ga^{3+}.

22. The complex according to claim 16, wherein said disorder is associated with at least one of elevated levels of pro-inflammatory cytokine/s and reduced levels of anti-inflammatory cytokine/s.

23. The complex according to claim 22, wherein said disorder is at least one of inflammatory, infectious, autoimmune, proliferative, ischemic, metabolic, autoimmune, neuro-degenerative disorder, spinal cord injury and trauma, and acute or chronic wound or injury.

24. The complex according to claim 23, wherein inflammatory disorder is at least one of inflammatory skin disorder/s, inflammatory bowel disease/s (IBD), arthritis, and inflammatory respiratory disorder/s.

25. The complex according to claim 24, wherein said inflammatory disorder is at least one of, at least one chronic or acute inflammatory skin disorder and at least one acute or chronic wound or injury.

26. The complex according to claim 23, wherein said disorder is an infectious disease caused by at least one of bacterial pathogen/s, viral pathogen/s and a parasite/s.

27. The complex according to claim 26, wherein said bacterial pathogen is at least one of enteropathogenic *Escherichia coli (EPEC), Pseudomonas aeruginosa* and *Staphylococcus aureus*.

28. The complex according to claim 26, wherein said viral pathogen is at least one of herpes, hepatitis viruses, influenza viruses, adeno-viruses, papova-viruses and pox viruses.

29. The complex according to claim 23, wherein said proliferative disorder is a malignancy associated with at least one of elevated level/s of pro-inflammatory cytokines and reduced level/s of anti-inflammatory cytokines.

30. The complex according to claim 23, wherein said metabolic disorder, is at least one of diabetes mellitus type I, diabetes mellitus type II and any diabetes related conditions.

31. A complex of nocardamine with zinc or any ionic forms thereof, wherein the formulation of the complex has a pH of 7.0 or 7.06.

32. The complex according to claim 31, wherein at least one metal ion is Zn^{2+}.

33. The complex according to claim 32, wherein said complex is a Nocardamine complex with Zn^{2+}.

34. A complex according to any one of claims 31 to 33, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof.

35. A kit comprising:

(i) at least one metal wherein at least one metal is zinc or any ionic form thereof , and

(ii) nocardamine, or a pharmaceutically acceptable derivative thereof; wherein a complex formed by said kit has a pH of 7.0 or 7.06.

36. The kit according to claim 35, for use in a method of treating, preventing, inhibiting, reducing, eliminating, protecting or delaying the onset of a pathological condition or a disorder in a subject in need thereof.

37. A composition comprising at least one complex of nocardamine with zinc or any ionic form thereof, wherein the complex has a pH of 7.0 or 7.06.

38. The composition according to claim 37, wherein at least one metal ion is Zn^{2+}.

39. The composition according claim 38, wherein said complex is nocardamine with Zn^{2+}.

40. The composition according to any one of claims 37 to 39, wherein said composition is a pharmaceutical composition, said composition comprises at least one pharmaceutically acceptable carrier/s, diluent/s, excipient/s.